Nina S. Kjellson Sells 11,078 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total value of $179,131.26. Following the completion of the transaction, the director now directly owns 472,207 shares of the company’s stock, valued at approximately $7,635,587.19. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA opened at $16.39 on Friday. The business has a fifty day moving average of $22.51 and a two-hundred day moving average of $19.87. Tyra Biosciences, Inc. has a 52-week low of $10.60 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. On average, analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Analysts Set New Price Targets

TYRA has been the subject of several recent research reports. Oppenheimer increased their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. HC Wainwright increased their price objective on Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Piper Sandler initiated coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $31.40.

Institutional Trading of Tyra Biosciences

Several large investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its holdings in shares of Tyra Biosciences by 43.9% during the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares during the period. BVF Inc. IL grew its holdings in shares of Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares during the period. Perceptive Advisors LLC grew its holdings in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after purchasing an additional 338,208 shares during the period. Ally Bridge Group NY LLC purchased a new position in shares of Tyra Biosciences during the 2nd quarter worth $4,232,000. Finally, Ensign Peak Advisors Inc purchased a new position in shares of Tyra Biosciences during the 2nd quarter worth $3,047,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.